TSXV:TRL.H - Post by User
Post by
LTOWNERon Apr 20, 2012 11:03am
387 Views
Post# 19816459
Another 'Buy' Recommendation
Another 'Buy' Recommendation
Post says fund manager adds to Trimel holdings
2012-04-20 10:41 ET - In the News
The Financial Post reports in its Friday edition that Steven Palmer at AlphaNorth Asset Management says buy Trimel Pharmaceuticals ($4.25). The Post's Jonathan Ratner, writing in Buy & Sell, says Mr. Palmer recently added to his Trimel holding in the AlphaNorth Growth Fund. He figures Trimel is in a good position, going after large markets with multiple drugs. For instance, it is in phase III trials for a testosterone replacement therapy for men and will soon begin a second phase II trial for a female sexual dysfunction treatment. It also has other earlier-stage products in the pipeline. "Management is highly experienced and were previously very successful at Biovail," Mr. Palmer said. The company's biggest potential risk is problems with clinical trials.